Therefore, future development and evaluation of novel regimens targeting the activated PI3K/AKT/mTOR pathway for the purpose of translating high antitumor activity to prolonged survival benefit is warranted in larger prospective clinical trials for the treatment cervical carcinoma, especially squamous cell carcinoma. This evidence concerns the gene PIK3CA and cervical carcinoma.